Deborah F. Aghib, Ph.D., managing director of the healthcare practice at Cassel Salpeter & Co., has 26 years of executive experience, broad scientific knowledge, and significant international experience in developing long-term strategies for business development, licensing, assets spinoffs, and mergers and acquisitions in the therapeutics, medical devices, companion diagnostics, platform technologies, analytical instrument fields, telemedicine, and AI and data intensive-driven technologies.
Prior to joining Cassel Salpeter, Dr. Aghib was a private equity consultant for CRG LP, a healthcare-focused investment firm. Before this, she served as a chief business development executive for Stellar Biotechnologies (Nasdaq:SBOT). Previously, she was the Vice President of Business Development and Strategy for Neuro-Zone SRL, a biotechnology company supporting drug discovery studies of cell to cell interactions in inflammation and age-related pathologies.
Dr. Aghib has held a host of director and advisory roles in the technology and biotechnology environment. Currently, Dr. Aghib serves as a Board Member of the OpenWorm Foundation.
Dr. Aghib was an Independent Director on the Stellar Biotechnology Board of Directors (formerly Nasdaq:SBOT), and a member of its Strategic Investment, M&A, Audit, and Corporate Governance committees.
Dr. Aghib also served as the Board Advisor to CellPly Srl, a data intensive personalized cancer therapy in vitro diagnostic company, ImmunGene, and Neuro-Zone Srl.
Dr. Aghib holds a Ph.D. in Molecular and Cellular Biology from the University of Milan (Italy) and a Ph.D. in Human Genetics from the University of Pavia (Italy), a Bachelor’s/Master’s degree in Biological Sciences from the University of Milan (Italy), and an Advanced Post-Graduate in Industry 4.0: Innovation, Artificial Intelligence and Robotics from the University S. Anna, Pisa (Italy).